Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Advanced Liver Therapies at St. Luke's Episcopal Hospital
991
mi
from 43215
Houston, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Advanced Liver Therapies at St. Luke's Episcopal Hospital
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Houston Methodist Hospital
995
mi
from 43215
Houston, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Houston Methodist Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Houston Methodist
991
mi
from 43215
Houston, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Houston Methodist
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Utah Health Sciences Center
1511
mi
from 43215
Salt Lake City, UT
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Utah Health Sciences Center
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Virginia Health System
275
mi
from 43215
Charlottesville, VA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Virginia Health System
275
mi
from 43215
Charlottesville, VA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
NYU Langone Medical Center
478
mi
from 43215
New York, NY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
NYU Langone Medical Center
478
mi
from 43215
New York, NY
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Status: Enrolling
Updated:  4/5/2017
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)
Status: Enrolling
Updated: 4/5/2017
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) in Motion
Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.
Status: Enrolling
Updated:  5/4/2017
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Magnetic Resonance Imaging (MRI) in Motion
Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.
Status: Enrolling
Updated: 5/4/2017
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  5/17/2017
U.S.C./Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 5/17/2017
U.S.C./Norris Comprehensive Cancer Center
1970
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  5/17/2017
University of Colorado Cancer Center
1154
mi
from 43215
Aurora, CO
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 5/17/2017
University of Colorado Cancer Center
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  5/17/2017
Indiana University Simon Cancer Center
167
mi
from 43215
Indianapolis, IN
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 5/17/2017
Indiana University Simon Cancer Center
167
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  5/17/2017
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 5/17/2017
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  5/17/2017
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 5/17/2017
Fox Chase Cancer Center
420
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated:  5/17/2017
Massachussetts General Hospital
643
mi
from 43215
Boston, MA
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Status: Enrolling
Updated: 5/17/2017
Massachussetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated:  5/23/2017
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer
Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy
Status: Enrolling
Updated: 5/23/2017
Mayo Clinic Arizona
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated:  6/7/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated: 6/7/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated:  6/7/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated: 6/7/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated:  6/7/2017
4428
mi
from 43215
Rozzano,
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma
Status: Enrolling
Updated: 6/7/2017
4428
mi
from 43215
Rozzano,
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
993
mi
from 43215
Miami, FL
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
620
mi
from 43215
Westwood, KA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
620
mi
from 43215
Westwood, KA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
481
mi
from 43215
New York, NY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
355
mi
from 43215
Rochester, NY
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
994
mi
from 43215
Galveston, TX
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
994
mi
from 43215
Galveston, TX
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
327
mi
from 43215
Washington, D.C.,
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
327
mi
from 43215
Washington, D.C.,
Click here to add this to my saved trials
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  6/13/2017
509
989
mi
from 43215
Graz,
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 6/13/2017
509
989
mi
from 43215
Graz,
Click here to add this to my saved trials
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
274
mi
from 43215
Chicago, IL
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/15/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/15/2017
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/15/2017
University of California at San Francisco
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors
Status: Enrolling
Updated:  6/22/2017
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors
Status: Enrolling
Updated: 6/22/2017
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated:  6/26/2017
Mayo Clinic Cancer Center
559
mi
from 43215
Rochester, MN
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Status: Enrolling
Updated: 6/26/2017
Mayo Clinic Cancer Center
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)
Status: Enrolling
Updated:  6/26/2017
University of Chicago
274
mi
from 43215
North Chicago, IL
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)
Status: Enrolling
Updated: 6/26/2017
University of Chicago
274
mi
from 43215
North Chicago, IL
Click here to add this to my saved trials
Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Status: Enrolling
Updated:  7/10/2017
UC Davis Medical Center
2043
mi
from 43215
Sacramento, CA
Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Status: Enrolling
Updated: 7/10/2017
UC Davis Medical Center
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation
Circulating MicroRNA Isoforms as Biomarkers in Hepatocellular Carcinoma and Associated Liver Transplantation
Status: Enrolling
Updated:  7/17/2017
Baylor University Medical Center
910
mi
from 43215
Dallas, TX
Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation
Circulating MicroRNA Isoforms as Biomarkers in Hepatocellular Carcinoma and Associated Liver Transplantation
Status: Enrolling
Updated: 7/17/2017
Baylor University Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery
Surgical Outcomes Database for Faculty of Hepatopancreatico Biliary Surgery
Status: Enrolling
Updated:  7/31/2017
Carolinas Health System
348
mi
from 43215
Charlotte, NC
Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery
Surgical Outcomes Database for Faculty of Hepatopancreatico Biliary Surgery
Status: Enrolling
Updated: 7/31/2017
Carolinas Health System
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006
Status: Enrolling
Updated:  8/22/2017
Leo W Jenkins Cancer Center at East Carolina University School of Medicine
429
mi
from 43215
Greenville, NC
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006
Status: Enrolling
Updated: 8/22/2017
Leo W Jenkins Cancer Center at East Carolina University School of Medicine
429
mi
from 43215
Greenville, NC
Click here to add this to my saved trials
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated:  8/28/2017
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
Status: Enrolling
Updated: 8/28/2017
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  8/30/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 8/30/2017
Masonic Cancer Center at University of Minnesota
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated:  9/7/2017
Phoenix Children's Hospital
1658
mi
from 43215
Phoenix, AZ
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated: 9/7/2017
Phoenix Children's Hospital
1658
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated:  9/7/2017
Southern California Permanente Medical Group
1973
mi
from 43215
Downey, CA
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated: 9/7/2017
Southern California Permanente Medical Group
1973
mi
from 43215
Downey, CA
Click here to add this to my saved trials
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated:  9/7/2017
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated: 9/7/2017
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated:  9/7/2017
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated: 9/7/2017
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated:  9/7/2017
Alfred I. duPont Hospital for Children
396
mi
from 43215
Wilmington, DE
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
Status: Enrolling
Updated: 9/7/2017
Alfred I. duPont Hospital for Children
396
mi
from 43215
Wilmington, DE
Click here to add this to my saved trials